Leerink Swann Downgrades Savient Pharmaceuticals (SVNT) to Market Perform; M&A, Launch and Competitive Uncertainty
Tweet Send to a Friend
Leerink Swann downgrades Savient Pharmaceuticals (Nasdaq: SVNT) from Outperform to Market Perform. PT lowered from $22 to $20.
Leerink analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Leerink analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
